What is anti-HIgG(Fc)-N-DM1 ADC?

The anti-HIgG(Fc)-N-DM1 ADC consists of an anti-human IgG Fc specific polyclonal antibody linked to DM1 via a noncleavable linker. DM1 is a cytotoxic molecule that binds to tubulins, disrupting microtubule dynamics and inducing cell death.

What are the primary applications of anti-HIgG(Fc)-N-DM1 ADC?

This ADC is primarily used in research settings to target cells that express Fc receptors, making it useful in studying diseases such as certain cancers where these receptors are overexpressed.

How does the anti-HIgG(Fc)-N-DM1 ADC specifically target tumor cells in research models?

In experimental models, this ADC targets tumor cells that express receptors for the Fc portion of human IgG. The specificity of targeting is based on the presence of these receptors, which are often overexpressed in certain tumor types. This allows for selective delivery of the cytotoxic drug, DM1, to tumor cells while sparing normal tissues.

What experimental conditions optimize the use of anti-HIgG(Fc)-N-DM1 ADC?

Optimal experimental conditions for using the ADC include maintaining physiological pH and temperature during experiments. Researchers should also consider the expression levels of Fc receptors on the target cells to ensure effective binding and internalization of the ADC.

How can the efficacy of anti-HIgG(Fc)-N-DM1 ADC be quantified in laboratory settings?

The efficacy of this ADC in laboratory settings can be quantified by measuring cell viability assays, apoptosis induction, and cell cycle analysis post-treatment. Additionally, researchers may use imaging techniques to directly observe the disruption of microtubule structures within treated cells.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-HIgG(Fc)-N-DM1 ADC

anti-HIgG(Fc)-N-DM1 ADC (CAT#: ADC-AA-008)

This ADC product is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1. The antibody portion is a secondary antibody and the drug portion, DM1, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
anti-human IgG Fc specific polyclonal IgG antibody

Species Reactivity
Human

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-008. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The Anti-HIgG(Fc)-N-DM1 ADC from Creative Biolabs has exceeded our expectations. Excellent for targeting microtubule dynamics, resulting in effective cell death with no unwanted toxicity.

Excellent

Remarkably effective

This ADC's precision in delivering DM1 ensures targeted disruption of tubulins, making it a vital tool in our cytotoxic studies.

Excellent

Anti-HIgG(Fc)-N-DM1 ADC provides dependable results in our lab. The noncleavable linker ensures stable delivery of DM1, enhancing the efficacy of our monoclonal antibody screenings.

Excellent

I highly recommend Anti-HIgG(Fc)-N-DM1 ADC for advanced cancer research. Its targeted action on tubulins and subsequent induction of cell death are incredibly effective and safe.

Excellent

Anti-HIgG(Fc)-N-DM1 ADC has proven to be an indispensable asset in our lab, providing consistent and reliable results in targeted cytotoxicity without primary antibody use.

Q: 1: What is anti-HIgG(Fc)-N-DM1 ADC?
A: The anti-HIgG(Fc)-N-DM1 ADC consists of an anti-human IgG Fc specific polyclonal antibody linked to DM1 via a noncleavable linker. DM1 is a cytotoxic molecule that binds to tubulins, disrupting microtubule dynamics and inducing cell death.
Q: 2: What are the primary applications of anti-HIgG(Fc)-N-DM1 ADC?
A: This ADC is primarily used in research settings to target cells that express Fc receptors, making it useful in studying diseases such as certain cancers where these receptors are overexpressed.
Q: 3: How does the anti-HIgG(Fc)-N-DM1 ADC specifically target tumor cells in research models?
A: In experimental models, this ADC targets tumor cells that express receptors for the Fc portion of human IgG. The specificity of targeting is based on the presence of these receptors, which are often overexpressed in certain tumor types. This allows for selective delivery of the cytotoxic drug, DM1, to tumor cells while sparing normal tissues.
Q: 4: What experimental conditions optimize the use of anti-HIgG(Fc)-N-DM1 ADC?
A: Optimal experimental conditions for using the ADC include maintaining physiological pH and temperature during experiments. Researchers should also consider the expression levels of Fc receptors on the target cells to ensure effective binding and internalization of the ADC.
Q: 5: How can the efficacy of anti-HIgG(Fc)-N-DM1 ADC be quantified in laboratory settings?
A: The efficacy of this ADC in laboratory settings can be quantified by measuring cell viability assays, apoptosis induction, and cell cycle analysis post-treatment. Additionally, researchers may use imaging techniques to directly observe the disruption of microtubule structures within treated cells.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins

CAT#	Product Name	Linker	Payload
ADC-AA-039	anti-Rat IgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-034	anti-RIgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-001	anti-HIgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-009	anti-HIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-AA-050	Protein G-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-484	Anti-CD22-MCC-DM1 ADC-11	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-496	Anti-EGFR-SMCC-DM1 ADC	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-495	Anti-EGFR-SMCC-DM1 ADC-4	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-541	Anti-CD44-DM1 ADC		DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.